Tralokinumab for moderate-to-severe UC: A randomised, double-blind, placebo-controlled, phase IIa study

Gut

Volumn 64, Issue 2, 2015, Pages 243-249

  Danese, Silvio ^a   Rudziński, Janusz ^b   Brandt, Wolfgang ^c   Dupas, Jean Louis ^d   Peyrin Biroulet, Laurent ^e   Bouhnik, Yoram ^f   Kleczkowski, Dariusz ^g   Uebel, Peter ^h   Lukas, Milan ⁱ   Knutsson, Mikael ^j   Erlandsson, Fredrik ^j   Hansen, Mark Berner ^j   Keshav, Satish ^k  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b 10 Wojskowy Szpital Kliniczny Z Polikliniką ^*  (Poland)

^c Facharzt fir innere Medizin Psychotherapie   (Germany)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f BEAUJON HOSPITAL   (France)

^g Quality Assurance Department   (Poland)

^h P Uebel Haus der Gesundheit   (Germany)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j ASTRAZENECA R AND D   (Sweden)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TRALOKINUMAB; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DECREASED APPETITE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEALING; HEMORRHOID; HUMAN; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; TOOTH PAIN; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; ADOLESCENT; CLINICAL TRIAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; INTESTINE MUCOSA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; WOUND HEALING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84920942417     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308004     Document Type: Article

References (21)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25.
2. Rubin DT, Dubinsky MC, Panaccione R, et al. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2010;55:1044-52.
3. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241-7.
4. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
5. Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther 2013;37:855-66.
6. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011;34:1-10.
7. Fuss IJ, Strober W. The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol 2008;1(Suppl 1):S31-3.
8. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
9. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
10. Jovani M, Fiorino G, Danese S. Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. Curr Drug Targets 2013;14:1444-52.
11. May RD, Monk PD, Cohen ES, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012;166:177-93.
12. Oh CK, Faggioni R, Jin F, et al. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol 2010;69:645-55.
13. Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41:330-8.
14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
15. Christophi GP, Rong R, Holtzapple PG, et al. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2012;18:2342-56.
16. Verma R, Verma N, Paul J. Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level. Eur Cytokine Netw 2013;24:130-8.
17. Biancheri P, Di Sabatino A, Ammoscato F, et al. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol 2014;44:370-85.
18. European Medicines Agency. Guideline on the development of new medicinal products for the treatment of ulcerative colitis. London: European Medicines Agency, 2008.
19. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-46.
20. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87; quiz e85-6.
21. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149-57.e2.